Literature DB >> 16340538

neovascular age-related macular degeneration: Natural History and Treatment Outcomes.

Daniel Pauleikhoff1.   

Abstract

BACKGROUND: This review summarizes the data reported in peer-reviewed literature and presents current knowledge on differentiation, natural history, and therapeutic outcomes of neovascular age-related macular degeneration (AMD).
METHODS: The MEDLINE database was searched to review natural history of neovascular AMD and therapeutic effects of available treatments.
RESULTS: The search produced>7,000 articles. Research suggests that fluorescein angiographic characterization of location, composition, and size of neovascular lesions may be important in prognosis and should be considered for evaluation of treatment benefits in conjunction with evidence of recent disease progression for lesions not composed of predominantly classic choroidal neovascularization (CNV). Laser photocoagulation, photodynamic therapy with verteporfin, and administration of pegaptanib sodium reduce the risk of vision loss in selected cases of neovascular AMD, while submacular surgery can reduce the risk of severe visual acuity loss in selected cases of predominantly hemorrhagic CNV; further approaches are under investigation.
CONCLUSION: Visual prognosis of neovascular AMD is variable according to lesion location, composition, and size. Often, lesions have a poor prognosis, resulting in rapid and progressive loss of visual acuity and contrast sensitivity. Such losses have a profound effect on patients' quality of life and ability to perform everyday tasks. Reducing the risk of further loss of visual acuity and contrast sensitivity might enable patients with neovascular AMD to maintain better functional abilities.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16340538     DOI: 10.1097/00006982-200512000-00016

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  22 in total

1.  Early neovascular bridging of choroidal neovascularization after ranibizumab treatment.

Authors:  Juan Reche-Frutos; Cristina Calvo-Gonzalez; Juan Donate-Lopez; Julian Garcia-Feijoo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-07-21       Impact factor: 3.117

2.  Comparison of serum thiol-disulphide homeostasis and total antioxidant-oxidant levels between exudative age-related macular degeneration patients and healthy subjects.

Authors:  Ahmet Elbay; Omer Faruk Ozer; Julide Canan Umurhan Akkan; Ugur Celik; Işıl Kutlutürk; Arif Koytak; Hakan Ozdemir
Journal:  Int Ophthalmol       Date:  2016-10-12       Impact factor: 2.031

3.  Quantitative assessment of choriocapillaris flow deficits in eyes with macular neovascularization.

Authors:  Federico Corvi; Mariano Cozzi; Giulia Corradetti; Giovanni Staurenghi; David Sarraf; SriniVas R Sadda
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-01-08       Impact factor: 3.117

4.  A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.

Authors:  Dae Hyun Park; Hae Jung Sun; Sung Jin Lee
Journal:  Int Ophthalmol       Date:  2016-11-08       Impact factor: 2.031

5.  Risk of scar in the comparison of age-related macular degeneration treatments trials.

Authors:  Ebenezer Daniel; Cynthia A Toth; Juan E Grunwald; Glenn J Jaffe; Daniel F Martin; Stuart L Fine; Jiayan Huang; Gui-shuang Ying; Stephanie A Hagstrom; Katrina Winter; Maureen G Maguire
Journal:  Ophthalmology       Date:  2013-12-04       Impact factor: 12.079

Review 6.  Molecular mechanisms of subretinal fibrosis in age-related macular degeneration.

Authors:  Keijiro Ishikawa; Ram Kannan; David R Hinton
Journal:  Exp Eye Res       Date:  2015-03-13       Impact factor: 3.467

7.  Sensitivity and specificity of optical coherence tomography angiography in the diagnosis of active choroidal neovascularization: a systematic review and meta-analysis.

Authors:  Miao Wang; Sheng Gao; Yun Zhang; Meixia Zhang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-06-10       Impact factor: 3.117

Review 8.  Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.

Authors:  Michael Waisbourd; Anat Loewenstein; Michaella Goldstein; Igal Leibovitch
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

9.  Clinical phenotypes associated with the complement factor H Y402H variant in age-related macular degeneration.

Authors:  Milam A Brantley; Sean L Edelstein; Jennifer M King; Rajendra S Apte; Steven M Kymes; Alan Shiels
Journal:  Am J Ophthalmol       Date:  2007-07-12       Impact factor: 5.258

10.  Intravitreal Bevacizumab versus Combined Bevacizumab and Triamcinolone Acetonide for Neovascular Age-Related Macular Degeneration.

Authors:  Mohammad Riazi-Esfahani; Hamid Ahmadieh; Hooshang Faghihi; Niloofar Piri; Ramin Taei; Reza Karkhaneh; Zahra Alami-Harandi; Alireza Lashay; Ahmad Mirshahi; Mehdi Nili-Ahmadabadi; Masoud Soheilian; Masoumeh Sanagou
Journal:  J Ophthalmic Vis Res       Date:  2008-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.